COX-2 Advisory Committee May Decide Fate of Pfizer’s Bextra
Executive Summary
The commercial future of Pfizer's Bextra may be at stake during FDA's early 2005 advisory committee discussion of the COX-2 inhibitor class
You may also be interested in...
Merck May Need New Arcoxia Trial Design Prior To FDA Approval
Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program
Merck May Need New Arcoxia Trial Design Prior To FDA Approval
Merck may need to conduct additional Arcoxia clinical trials to gain FDA approval after the agency and its COX-2 inhibitor advisory committee cited flaws in the existing program
FDA Issues Caution On COX-2s, But Leaves Open Possibility For First-Line Use
FDA's caution on the use of COX-2 inhibitors leaves open the possibility for patients to use Pfizer's Celebrex and Bextra as first-line therapies